6 ADVERSE REACTIONS

What Are Warnings and Precautions for Tadalafil ( Vasostrict, ADH)?
More about Cialis (tadalafil)
17.3 Concomitant Use with Drugs Which Lower Blood Pressure
2.1 Pulmonary Arterial Hypertension
2.6 Use in Specific Populations

Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labelling:Hypotension [see Warnings and Precautions (5.1)]Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]Hearing loss [see Warnings and Precautions (5.4)]Priapism [see Warnings and Precautions (5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil 40 mg was 4% compared to 5% in placebo-treated patientsIn the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity.

What Are Warnings and Precautions for Tadalafil ( Vasostrict, ADH)?

It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous — Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]. Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.6) and Patient Counseling Information (17)]. Urogenital — Priapism [see Warnings and Precautions (5.6)].

Cost Comparison

7 DRUG INTERACTIONS 7.1 NitratesAdministration of nitrated within 48 hours after the last dose of tadalafil tablets is contraindicated [see Contraindications (4.1)].7.2 Alpha BlockersPDE5 inhibitors, including tadalafil, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology (12.2)].7.4 AlcoholBoth alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood pressure–lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations [see Clinical Pharmacology (12.2)].7.5 CYP3A Inhibitors/InducersRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity.

Texture	Description	Feel	Typical Surface Finish
Smooth	Standard surface, glossy	Smooth	Glossy or matte
Textured	Slightly ridged or indented	Slightly rough	Matte or semi-matte
Coated	Coatings for identification	Varies	Glossy or matte

Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous — Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)].Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or 60 mg generic cialis to other factors [see Warnings and Precautions (5.6) and Patient Counseling Information (17)].Urogenital — Priapism [see Warnings and Precautions (5.6)].

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	40mg	60 + 6 Pills	130.98€ 124.74€
Cialis Generic	60mg	30 + 2 Pills	85.33€ 81.27€
Cialis Super Active	20mg	270 + 30 Pills	661.49€ 629.99€
Cialis Soft Tabs	20mg	30 + 4 Pills	87.43€ 83.27€
Cialis Generic	60mg	20 Pills	65.61€ 62.49€
Cialis Generic	10mg	180 + 8 Pills	236.88€ 225.60€
Cialis Super Active	20mg	90 + 10 Pills	314.14€ 299.18€
Cialis Soft Tabs	20mg	20 + 2 Pills	66.98€ 63.79€
Cialis Generic	10mg	20 Pills	48.23€ 45.93€
Cialis Professional	40mg	270 + 6 Pills	898.37€ 855.59€
Cialis Original	20mg	120 + 8 Pills	497.29€ 473.61€
Cialis Generic	10mg	120 + 6 Pills	178.49€ 169.99€
Cialis Super Active	20mg	180 + 20 Pills	521.59€ 496.75€
Cialis Super Active	20mg	120 + 16 Pills	382.15€ 363.95€
Cialis Generic	2.5mg	120 + 6 Pills	128.93€ 122.79€

The following serious adverse reactions are discussed elsewhere in the labelling: Hypotension [see Warnings and Precautions (5.1)] Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)] Hearing loss [see Warnings and Precautions (5.4)] Priapism [see Warnings and Precautions (5.6)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Cialis pills are frequently bright orange with an oval shape.
Imprints include logos or dosage numbers.
The surface is glossy and smooth to the touch.
The form aids in swallowing comfortably.
They are small, usually about 10 mm in size.
The shape is elongated with rounded edges.
Markings help prevent fake or counterfeit pills.

Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil 40 mg was 4% compared to 5% in placebo-treated patients In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil 40 mg group and occurring more frequently than with placebo. The following adverse reactions have been identified during post-approval use of tadalafil. Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous — Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]. Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.6) and Patient Counseling Information (17)]. Urogenital — Priapism [see Warnings and Precautions (5.6)]. 7 DRUG INTERACTIONS 7.1 NitratesAdministration of nitrated within 48 hours after the last dose of tadalafil tablets is contraindicated [see Contraindications (4.1)].7.2 Alpha BlockersPDE5 inhibitors, including tadalafil, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology (12.2)].7.4 AlcoholBoth alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators.

The pill's appearance is documented in the official prescribing information.
This document is called the package insert or label.
The "Description" section details shape, color, and imprint.
This information is legally required for all prescription drugs.
The appearance description helps pharmacists verify dispensing.
It also aids law enforcement in identifying diverted pharmaceuticals.
Customs officials may use appearance to spot illegal shipments.
The distinct look makes it less likely to be accidentally ingested.
It is not attractive to children due to its plain, medicinal look.
Child-resistant packaging further complements the safety design.
The appearance supports the overall safe use ecosystem.

When mild vasodilators are taken in combination, blood pressure–lowering effects of each individual compound may be increased.

More about Cialis (tadalafil)

How Long Does It Take For Results?

The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil 40 mg was 4% compared to 5% in placebo-treated patientsIn the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations [see Clinical Pharmacology (12.2)].7.5 CYP3A Inhibitors/InducersRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil.

17.3 Concomitant Use with Drugs Which Lower Blood Pressure

At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)]. Administration of nitrated within 48 hours after the last dose of tadalafil tablets is contraindicated [see Contraindications (4.1)]. PDE5 inhibitors, including tadalafil, and alpha–adrenergic blocking agents are both vasodilators 60 mg cialis with blood-pressure-lowering effects. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)].

When Pills Don't Work

PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology (12.2)]. Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations [see Clinical Pharmacology (12.2)]. Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)]. Administration of nitrated within 48 hours after the last dose of tadalafil tablets is contraindicated [see Contraindications (4.1)]. PDE5 inhibitors, including tadalafil, and alpha–adrenergic blocking agents are both vasodilators 60 mg cialis with blood-pressure-lowering effects. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)].

2.1 Pulmonary Arterial Hypertension

Real Success Rates

PDE5 inhibitors, including tadalafil, are mild systemic vasodilators.

2.6 Use in Specific Populations

Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity. Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous — Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)].Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or 60 mg generic cialis to other factors [see Warnings and Precautions (5.6) and Patient Counseling Information (17)].Urogenital — Priapism [see Warnings and Precautions (5.6)]. The following serious adverse reactions are discussed elsewhere in the labelling: Hypotension [see Warnings and Precautions (5.1)] Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)] Hearing loss [see Warnings and Precautions (5.4)] Priapism [see Warnings and Precautions (5.6)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Are certain side effects more common if I take Cialis daily?

Digital pill identifiers (like apps) use the appearance for verification.
Patients can enter color, shape, and imprint to identify a pill.
The National Institutes of Health (NIH) database includes its image.
The image is usually a high-resolution, color-accurate photograph.
Some websites offer 360-degree views of the pill.
This digital documentation aids in global health safety.
The appearance is a static property; it does not animate or change.
The pill is inanimate and has no electronic components.
Its entire purpose is to deliver the drug tadalafil.
The appearance is the primary human-interface for the drug.
It bridges the chemical formulation and the patient.

Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations [see Clinical Pharmacology (12.2)]. Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)]. Tadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)]. For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology (12.3)].